Associated Genetic Biomarkers
NCI Definition: A rare histological variant of glioblastoma (WHO grade IV) characterized by a biphasic tissue pattern with alternating areas displaying glial and mesenchymal differentiation (WHO). 
Gliosarcomas most frequently harbor alterations in TP53, PTEN, NF1, RB1, and CDKN2A .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PTEN Mutation, and CDKN2A Loss are the most common alterations in gliosarcoma .
There are 47 clinical trials for gliosarcoma, of which 42 are open and 5 are completed or closed. Of the trials that contain gliosarcoma as an inclusion criterion, 2 are early phase 1 (2 open), 20 are phase 1 (18 open), 8 are phase 1/phase 2 (7 open), 13 are phase 2 (12 open), 3 are phase 2/phase 3 (3 open), and 1 is no phase specified (0 open).
MGMT, EGFR, and ERBB2 are the most frequent gene inclusion criteria for gliosarcoma clinical trials .
Temozolomide, radiation therapy, and bevacizumab are the most common interventions in gliosarcoma clinical trials.
Significant Genes in Gliosarcoma
EGFR is altered in 14.71% of gliosarcoma patients .
EGFR is an inclusion eligibility criterion in 3 clinical trials for gliosarcoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR status and gliosarcoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) .
ERBB2 is an inclusion eligibility criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) .
H3F3A is an inclusion eligibility criterion in 1 clinical trial for gliosarcoma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and gliosarcoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.